About
Who We Are
Leadership Team
Board of Directors
Clinical and Scientific Advisors
Contact
Science
Immune Continuum
Immunoglobulin E (IgE) in Allergic Conditions
CCR4 in Inflammation
CCR4 in Cancer
Publications
Pipeline
Snapshot
RPT904
Tivumecirnon (FLX475)
Investors
Corporate Profile
Press Releases
Events and Presentations
Stock Information
Corporate Governance
SEC Filings
Email Alerts
Investor Contact
Investor FAQs
Careers
Culture
Benefits
Open Positions
PRESS RELEASES
Year
2025
2024
2023
2022
2021
Filter
June 23 | 2025
RAPT Therapeutics Names Two Industry Veterans to its Board of Directors
June 13 | 2025
RAPT Therapeutics Announces Effective Date for 1-for-8 Reverse Stock Split
June 04 | 2025
RAPT Therapeutics to Participate in Upcoming Investor Conferences
May 08 | 2025
RAPT Therapeutics Reports First Quarter 2025 Financial Results
April 15 | 2025
RAPT Therapeutics Deepens Expertise in Allergic Diseases with Appointment of Jessica Savage, M.D., M.H.S., as Vice President, Clinical Development
March 07 | 2025
RAPT Therapeutics to Participate in Upcoming Investor Conferences
March 06 | 2025
RAPT Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results
January 09 | 2025
RAPT Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
January 06 | 2025
RAPT Therapeutics Names Lori Lyons-Williams Chair of the Company’s Board of Directors
December 23 | 2024
RAPT Therapeutics Announces $150 Million Private Placement
You are leaving RAPT.com to go to the eczema clinical trial study site.
